Biogen outlines Phase III ambitions for felzartamab in pipeline push
Biogen (Nasdaq: BIIB) has highlighted the growing role of felzartamab in its pipeline during a virtual investor seminar, spotlighting three late-stage studies focused on rare kidney diseases and a broader strategy to expand into immune-mediated conditions.
The investigational therapy, a CD38-targeting antibody originally developed by MorphoSys and acquired through Biogen’s 2024 purchase of Human Immunology Biosciences (HI-Bio), is central to the company’s repositioning beyond its neurology roots. Felzartamab is being advanced in three pivotal global Phase III trials, targeting antibody-driven kidney disorders with high unmet need.
Christopher Viehbacher, Biogen’s chief executive, said the company is building on recent product launches and aims to deliver novel treatments across a range of immune-mediated diseases, starting with three rare kidney diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze